Pfizer’s Growth Potential and Strategic Focus Justify Buy Rating Amid Healthcare Policy ...
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...